Fibrocell Science, Inc. (Nasdaq: FCSC) announced that the primary endpoints were not met in the Company’s Phase II clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments Trading Halts

Wedbush Remains Sidelined on Fibrocell Science (FCSC) Following Azficel-T Program Failure June 9, 2016 8:47 AM Roth Affirms Fibrocell Science (FCSC) at 'Buy' Following Azficel-T Phase 2 Miss in Vocal Cord ScarringJune 8, 2016 11:59 AM Fibrocell Reports Phase II azficel-T Trial for Treatment of Vocal Cord Scarring Did Not Meet Primary EndpointsJune 8, 2016 8:01 AM